A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]

FRX Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$6,499.94
Insider Selling (Last 12 Months): C$250,941.70

Fennec Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Fennec Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fennec Pharmaceuticals Share Price & Price History

Current Price: C$13.13
Price Change: Price Decrease of -0.49 (-3.60%)
As of 02/3/2023 01:00 AM ET

This chart shows the closing price history over time for FRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Click here for the full story

Fennec Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2022Chris Anigeron RallisDirectorSell333C$10.63C$3,538.6930,018
10/20/2022Chris Anigeron RallisDirectorSell2,068C$10.66C$22,035.3725,589
9/21/2022Robert Christopher AndradeSenior OfficerSell19,052C$11.02C$209,888.26176,721
9/12/2022Rostislav Christov RaykovDirectorSell16,666C$0.93C$15,479.3821,081,996
7/18/2022Chris Anigeron RallisDirectorBuy11,111C$0.59C$6,499.9432,036
8/17/2020Robert Christopher AndradeSenior OfficerSell12,874C$7.99C$102,914.76158,273
8/17/2020Rostislav Christov RaykovDirectorSell12,093C$7.99C$96,671.442,355,838
8/13/2020Robert Christopher AndradeSenior OfficerSell97,136C$8.64C$839,060.77248,875
8/13/2020Rostislav Christov RaykovDirectorBuy323,961C$1.85C$599,327.852,541,011
See Full Table

SEC Filings (Institutional Ownership Changes) for Fennec Pharmaceuticals (TSE:FRX)

Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Read More on Fennec Pharmaceuticals

Today's Range

Now: C$13.13
Low: C$13.13
High: C$13.13

50 Day Range

MA: C$13.36
Low: C$12.27
High: C$14.41

52 Week Range

Now: C$13.13
Low: C$5.94
High: C$14.41


118 shs

Average Volume

648 shs

Market Capitalization

C$344.81 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Fennec Pharmaceuticals?

Fennec Pharmaceuticals' top insider shareholders include:
  1. Rostislav Christov Raykov (Director)
  2. Robert Christopher Andrade (Senior Officer)
  3. Chris Anigeron Rallis (Director)
Learn More about top insider investors at Fennec Pharmaceuticals.
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
[Full Story]